BR112013029769B1 - Levedura recombinante compreendendo sequência de ácido nucleico que codifica h- ferritina, composição que a compreende e uso das mesmas - Google Patents

Levedura recombinante compreendendo sequência de ácido nucleico que codifica h- ferritina, composição que a compreende e uso das mesmas Download PDF

Info

Publication number
BR112013029769B1
BR112013029769B1 BR112013029769-7A BR112013029769A BR112013029769B1 BR 112013029769 B1 BR112013029769 B1 BR 112013029769B1 BR 112013029769 A BR112013029769 A BR 112013029769A BR 112013029769 B1 BR112013029769 B1 BR 112013029769B1
Authority
BR
Brazil
Prior art keywords
ferritin
iron
yeast
composition
brain
Prior art date
Application number
BR112013029769-7A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013029769A2 (pt
Inventor
James R. Connor
Ralph Lauren Keil
Original Assignee
Chyna Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chyna Llc filed Critical Chyna Llc
Publication of BR112013029769A2 publication Critical patent/BR112013029769A2/pt
Publication of BR112013029769B1 publication Critical patent/BR112013029769B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112013029769-7A 2011-05-24 2012-05-24 Levedura recombinante compreendendo sequência de ácido nucleico que codifica h- ferritina, composição que a compreende e uso das mesmas BR112013029769B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/114,429 US8778878B2 (en) 2007-01-29 2011-05-24 Use of ferritin to treat iron disorders
US13/114,429 2011-05-24
PCT/GB2012/000461 WO2012160333A2 (en) 2011-05-24 2012-05-24 Recombinant yeast

Publications (2)

Publication Number Publication Date
BR112013029769A2 BR112013029769A2 (pt) 2017-06-06
BR112013029769B1 true BR112013029769B1 (pt) 2021-09-28

Family

ID=46317426

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013029769-7A BR112013029769B1 (pt) 2011-05-24 2012-05-24 Levedura recombinante compreendendo sequência de ácido nucleico que codifica h- ferritina, composição que a compreende e uso das mesmas

Country Status (12)

Country Link
US (1) US8778878B2 (https=)
EP (1) EP2714888B1 (https=)
JP (1) JP2014516535A (https=)
CN (1) CN103635570A (https=)
AU (1) AU2012260682B2 (https=)
BR (1) BR112013029769B1 (https=)
CA (1) CA2874042C (https=)
DK (1) DK2714888T3 (https=)
ES (1) ES2659185T3 (https=)
NO (1) NO2714888T3 (https=)
PL (1) PL2714888T3 (https=)
WO (1) WO2012160333A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
EP1973549B1 (en) 2006-01-06 2016-07-20 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
US8778878B2 (en) * 2007-01-29 2014-07-15 Chyna, LLC Use of ferritin to treat iron disorders
US20170273906A1 (en) * 2014-08-21 2017-09-28 Ramot At Tel-Aviv University Ltd. Targeted liposomes encapsulating iron complexes and their uses
KR101811050B1 (ko) * 2015-09-02 2017-12-21 경북대학교 산학협력단 항염증성 폴리펩티드와 페리틴 모노머 단편이 접합된 융합폴리펩티드 및 이를 유효성분으로 포함하는 염증성 질환 예방 및 치료용 약학적 조성물
CN108503704A (zh) 2017-02-27 2018-09-07 昆山新蕴达生物科技有限公司 穿越血脑屏障的纳米药物载体
AU2019282169A1 (en) 2018-06-04 2021-01-21 Sidero Bioscience, Llc Compositions and methods for improvement of iron metabolism and gut microbiome health
EP3976636B1 (en) * 2019-05-28 2025-05-21 PreviPharma Consulting GmbH Method for preparing iron-depleted ferritin and use thereof
CN110759986B (zh) * 2019-10-18 2023-01-31 大连工业大学 一种可逆自组装蛋白的高效制备方法
CA3220586A1 (en) * 2021-05-19 2022-11-24 Sidero Bioscience, Llc Ferritin composition tolerability
KR102691733B1 (ko) * 2021-10-13 2024-08-05 전북대학교산학협력단 효모 유래 액포를 유효성분으로 포함하는 퇴행성 신경계 질환의 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100419530B1 (ko) * 2000-11-15 2004-02-19 주식회사 알엔에이 재조합 메탄올 자화 효모를 이용한 인간 페리틴의 대량생산 방법
KR100545981B1 (ko) * 2003-04-08 2006-01-25 전북대학교산학협력단 이종중합형 패리틴 생산방법
FR2898132B1 (fr) * 2006-03-01 2012-09-28 Mane Fils V Systeme d'expression d'un gene d'interet chez la levure
US8778878B2 (en) * 2007-01-29 2014-07-15 Chyna, LLC Use of ferritin to treat iron disorders
US8071542B2 (en) * 2007-01-29 2011-12-06 Chyna, LLC Use of ferritin to treat iron deficiency disorders
JP2011516419A (ja) * 2008-03-28 2011-05-26 カイナ エルエルシー 鉄欠乏性障害を治療するためのフェリチンの使用

Also Published As

Publication number Publication date
US8778878B2 (en) 2014-07-15
CA2874042A1 (en) 2012-11-29
EP2714888B1 (en) 2017-10-25
CN103635570A (zh) 2014-03-12
US20110287033A1 (en) 2011-11-24
WO2012160333A3 (en) 2013-03-07
EP2714888A2 (en) 2014-04-09
NO2714888T3 (https=) 2018-03-24
BR112013029769A2 (pt) 2017-06-06
PL2714888T3 (pl) 2018-06-29
AU2012260682A1 (en) 2013-05-02
AU2012260682B2 (en) 2015-07-30
ES2659185T3 (es) 2018-03-14
WO2012160333A2 (en) 2012-11-29
CA2874042C (en) 2020-10-06
JP2014516535A (ja) 2014-07-17
DK2714888T3 (da) 2018-01-29

Similar Documents

Publication Publication Date Title
BR112013029769B1 (pt) Levedura recombinante compreendendo sequência de ácido nucleico que codifica h- ferritina, composição que a compreende e uso das mesmas
US8071542B2 (en) Use of ferritin to treat iron deficiency disorders
US8795627B2 (en) Treatment of liver disorders by administration of RAP conjugates
EP2265113B1 (en) Use of ferritin to treat iron deficiency disorders
TW201212936A (en) Methods and compositions for intrathecal delivery of Alpha N-acetyglucosaminidase
Harrington Metabolic alkalosis
KR20220130258A (ko) 재조합 산 알파-글루코시다제를 포함하는 제형
CN111356474A (zh) 重组人类酸性α-葡萄糖苷酶
Sawitsky et al. The effect of pH on the distribution ofbilirubin in peripheral blood, cerebrospinal fluid, and fat tissues
Glader Wintrobe’s clinical hematology
US20140322162A1 (en) Use of Ferritin to Treat Iron Disorders
EP2143436B1 (en) Cd6 product for treatment of infectious diseases and related inflammatory processes
US20230212233A1 (en) Novel mutant of recombinant ganoderma lucidum immunomodulatory protein and use thereof
TWI828126B (zh) 用以治療高三酸甘油脂血症或其相關疾病的方法
Tsunogai et al. A novel NR3C2 mutation in a Japanese patient with the renal form of pseudohypoaldosteronism type 1
JP2014132029A (ja) 鉄欠乏性障害を治療するためのフェリチンの使用
CN120267849B (zh) 一种靶向双硫死亡的载6-氨基烟酰胺纳米材料及其制备方法和在卵巢癌中的应用
CN121622863A (zh) 低糖基化载脂蛋白d在制备用于血脑屏障修复的药物中的应用
WO2022240831A1 (en) Methods for increasing red blood cell half-life and associated treatment of anemia
CN119978063A (zh) 自组装小肽c16fw及其在制备治疗脑血管疾病的药物中的应用
TW201827060A (zh) 鋅鹽及鋅化合物用於促進紅血球生成之應用
Kawedia Molecular mechanisms that regulate the membrane water channel Aquaporin 5
HK1132930B (en) Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/05/2012, OBSERVADAS AS CONDICOES LEGAIS.